Sinopharm Group Co. Ltd.
SHTDY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $286 | $290 | $295 | $296 |
| % Growth | -1.3% | -1.7% | -0.3% | – |
| Cost of Goods Sold | $265 | $267 | $273 | $270 |
| Gross Profit | $21 | $22 | $22 | $25 |
| % Margin | 7.3% | 7.7% | 7.4% | 8.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $3 | $4 | $4 | $5 |
| SG&A Expenses | $13 | $13 | $12 | $13 |
| Sales & Mktg Exp. | $8 | $9 | $8 | $9 |
| Other Operating Expenses | $1 | $1 | $1 | $2 |
| Operating Expenses | $14 | $14 | $14 | $15 |
| Operating Income | $7 | $8 | $8 | $10 |
| % Margin | 2.5% | 2.7% | 2.8% | 3.5% |
| Other Income/Exp. Net | $0 | -$2 | -$1 | $0 |
| Pre-Tax Income | $7 | $6 | $8 | $11 |
| Tax Expense | $2 | $2 | $2 | $3 |
| Net Income | $3 | $3 | $4 | $5 |
| % Margin | 1.2% | 1.2% | 1.3% | 1.7% |
| EPS | 5.55 | 5.35 | 5.95 | 7.95 |
| % Growth | 3.7% | -10.1% | -25.2% | – |
| EPS Diluted | 5.55 | 5.35 | 5.95 | 7.95 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$1 |
| Interest Expense | $0 | $1 | $1 | $0 |
| Depreciation & Amortization | $2 | $1 | $1 | $1 |
| EBITDA | $10 | $11 | $10 | $13 |
| % Margin | 3.5% | 3.7% | 3.2% | 4.6% |